Antiviral therapy for HCV infection in an interferon-free age: shall we treat patients with decompensated cirrhosis before liver transplantation or with recurrent infection of the transplant?
The article analyzes literature data referring to the use of direct-acting antiviral drugs in patients with decompensated liver cirrhosis as an outcome of hepatitis C and in liver recipients with recurrent hepatitis C. A rationale for administering antiviral therapy of decompensated cirrhosis, limitations of its use before and after liver transplantation are discussed. The efficacy of antiviral therapy is considered in the aspect of virological (sustained response) and clinical outcomes in short-term and mediumterm perspectives. The results of analysis are compared with the current recommendations of the European Association for the Study of the Liver Результаты.